Injectable and implantable carrier systems based on modified poly(dicaroxylic acid-polyol esters) for controlled drug release
Patent Information
- Application Number
- DE502015016959
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-04-23
- Filing Date
- 2015-04-22
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2035-04-22
AI Technical Summary
Current biodegradable polymer-based carrier systems for controlled release of active ingredients face challenges such as complex degradation kinetics, acidic pH environments that can inactivate drugs, and difficulties in controlling release profiles, leading to inconsistent and unpredictable therapeutic outcomes.
The development of linear polyesters formed by esterification of dicarboxylic acids and polyhydric alcohols, which allow for the formation of polymers with free hydroxyl groups that can be covalently linked with active ingredients or fatty acids, enabling controlled release through enzymatic reactions and tailored lipophilicity.
This approach allows for the creation of injectable implants with controlled and reproducible release profiles, avoiding the limitations of acidic degradation and improving the bioavailability of active ingredients by using modified poly(dicarboxylic acid multiol esters that can be directly injected and form stable depots in the body.
Description
[0001] Delivery systems that release active substances in a controlled manner within the bodies of animals or humans are of great importance. Many highly potent drugs are characterized by low bioavailability after oral administration and a short half-life, which is due to rapid elimination or metabolism of the drug. Therapeutic use of such drugs is only possible with suitable delivery systems that are injected parenterally and release the drugs in a controlled manner. The duration of drug release depends on the indication. Release may be desired over a period of a few hours, days, weeks, or several months. Typical routes of administration include subcutaneous, intraperitoneal, or intramuscular injection. Furthermore, such delivery systems are also used, for example, for local therapy in the brain, eye, ear, bone marrow, and other organs.Depending on the indication, different release profiles, e.g., continuous or pulsatile, can be targeted. The drug delivery system should ensure a reproducible, controlled release of the active ingredient and be inert to the body.
[0002] Currently, both biodegradable and non-biodegradable carrier materials are used clinically. Non-biodegradable materials have the disadvantage that they must be removed from the body. Examples include the preparations Implanon® (Organon) and Vantas® (Orion Pharma), which must be removed from the body after 3 years and 12 months, respectively, thus requiring surgical intervention. The most commonly used biodegradable materials are polylactic acid and copolymers of lactic and glycolic acid. The monomers of these polymers are alpha-hydroxy acids. A disadvantage of these polymers is the complexity of their degradation. This is based on autocatalytic hydrolysis, which can lead to release kinetics that are difficult to control and very acidic pH values (pH 2) / 1, 2, 3 / . A further disadvantage is that the acidic microenvironment can degrade or inactivate active ingredients even before their release / 4,5 / .Most market preparations are either microparticles or pre-shaped implants (Red List 2014, Red List ®< Service GmbH).
[0003] Microparticles, also called microcapsules or microspherules, are solid, mostly spherical particles with a typical size in the lower micrometer range. Examples of biodegradable microparticles are Enantone® (Takeda), Sixantone® (Takeda), Decapeptyl® (Ferring), Sandostatin® LAR® (Sandoz), Pamorelin® LA 3.75 mg (Ipsen Pharma), Uropeptyl® Depot (Uropharm), and Risperdal® Consta® (Janssen-Cilag). The production of microparticles with a narrow and reproducible size distribution is very challenging and complex. The main methods used are coacervation, spray drying, or emulsion processes with solvent removal / 6 / . Furthermore, the microparticles must be mixed with the dispersion medium before application, which is time-consuming and often problematic due to the poor wettability of the particles.Incomplete emptying of the syringe and cannula clogging pose further problems in the administration of microparticles. The issue of residues from organic, mostly chlorinated solvents from the manufacturing process, as well as the complex manufacturing process under aseptic conditions and the difficulty of large-scale production, also limit this dosage form.
[0004] Examples of preformed solid implants include the market products Zoladex® (AstraZeneca), Profact® Depot (Sanofi), Leuprone® HEXAL® (Hexal), Leupro-Sandoz® (Sandoz), and Ozurdex® (Allergan Pharmaceuticals). A common problem with preformed solid implants is that a relatively large cannula is often required to insert the implant, which is frequently perceived as a foreign body and can cause pain.
[0005] Recent developments describe so-called "in situ implants." In this process, a low-viscosity fluid is injected into the body, which, upon receiving a stimulus (trigger), transforms into a depot (for example, a gel or a solid). This stimulus can be, for example, solvent exchange, thermogelation, or a chemical reaction (cross-linking) / 7 / . Cross-linking reactions are difficult to control in vivo, and toxicity problems with the cross-linking substances frequently occur. The most important thermogelling systems are poloxamer-based systems, chitosan-containing preparations, and low-molecular-weight pegylated polylactides or pegylated poly(lactide-co-glycolides). Disadvantages of these thermogelling systems include potential gelation prior to administration, stability problems of the excipients, excessively rapid release, and a lack of reproducibility in the release process.In contrast to other in situ systems, commercially available products exist for solvent-exchange-based systems. A typical example is Eligard®, which is distributed in Germany by Astellas. N-methylpyrrollidone (NMP) is used as the solvent, in which the matrix-forming polymer is dissolved. In the body, the mixing of endogenous water and NMP leads to reduced solubility and precipitation of the polymer. Disadvantages of this system include the inherent problems of autocatalytic polymer degradation associated with polylactides and poly(lactide-co-glycolides), which often result in difficult-to-control and fluctuating release rates.
[0006] The use of injectable polymers based on hydroxy esters is described in WO 2007 / 012979. However, a disadvantage is that covalent bonding of the active ingredient is only possible to a very limited extent or not at all, since only the end groups of the polymer can be modified. Furthermore, the polymers described in patent WO 2007 / 012979 offer only very limited control over their lipophilicity. Therefore, the use of biodegradable carrier materials whose lipophilicity can be tailored to the active ingredient would be a desirable objective.
[0007] As an alternative to polymer-based systems, lipid-based approaches are also described in the literature as parenteral delivery systems. These involve the production of drug-containing formulations by compression or extrusion of solid lipids. Disadvantages of lipid systems based on glycerol fatty acid esters (mono-, di-, or triglycerides) or waxes include limited control over lipophilicity and the occurrence of multiple polymorphic forms. This complex polymorphic behavior affects both the reproducibility of drug loading and release, as well as the biodegradability of the drug carriers. Patent DE 000003780862 describes solid lipid compresses administered via implantation. The patent WO 2009 / 080275 describes solid lipid implants which are manufactured by extrusion.
[0008] Furthermore, the production of lipid compresses and lipid extrudates is described in the patent. WO 2005 / 102284 described.EP 2 623 537 A1 discloses polycondensates obtainable by esterification of dicarboxylic acids with diols. WO2009 / 148583 discloses biodegradable thermoplastic polymers based on polyesters made from diols with dicarboxylic acids. EP1 374 860 A1 discloses polymer waxes whose backbone consists of polyesters made from dicarboxylic acids with polyols. EP 1 270 024 A1 discloses medical devices made from polymer wax obtainable from dicarboxylic acids and polyols by esterification.
[0009] The object of the invention was to provide an alternative to the biodegradable polymers based on monomers with a hydroxycarboxylic acid structure that have been used clinically to date. According to the invention, this problem was solved by linear polyesters, which are formed by the esterification of dicarboxylic acids and polyhydric alcohols (diols, triols, or higher alcohols). Figure 1 ) .
[0010] If substances with three or more hydroxyl groups are used as the alcohol component, free hydroxyl groups are available in the polymer backbone after polymerization, provided a suitable synthesis strategy is employed. Enzymatic reactions using divinyl-activated dicarboxylic acids are preferred because these yield defined linear polymers with defined free hydroxyl groups and avoid cross-linking / 8 / .
[0011] The free hydroxyl groups can be chemically reacted covalently with either active ingredients or with other excipients.
[0012] Little is known about covalent linkage with active pharmaceutical ingredients. Shafioul et al. published the chemical linkage of the active ingredient xanthorrhizol to poly(dicarboxylic acid multiol ester) and its enzymatic release / 9 / . In contrast, the esterification of poly(dicarboxylic acid multiol esters) with fatty acids has been described several times / 10-16 / , with the use of fatty acid-modified poly(dicarboxylic acid multiol esters) for the production of drug-containing micro- and nanoparticles. in vitro This is shown. However, the production of micro- and nanoparticles is complex and the particle size is often difficult to control.
[0013] According to the invention, it was first found that modified poly(dicarboxylic acid multiol ester) without further additives are suitable as injectable implants. The polymers can be used without Using an organic solvent, it can be injected directly.The invention relates to injectable carrier systems based on modified aliphatic polyesters for use in humans or animals with the aim of controlled release of a bioactive substance for therapeutic and / or diagnostic purposes, consisting of polymers whose basic structure is characterized by a comb-like arrangement of structural elements (A), (B) and (C), wherein the polymer backbone is formed by the structural elements (A) and (B), which consist of aliphatic dicarboxylic acids (A) and polyols (B) containing three or more OH groups, wherein two hydroxyl groups of the polyol (B) are esterified with the dicarboxylic acids of the structural element (A) to form a linear polymer backbone.After formation of the polymer backbone consisting of structural elements (A) and (B) and linked by ester bonds, when using triols and higher-grade polyols, one (in the case of triols) or several (number of hydroxyl groups in the polyol > 3) free hydroxyl groups are still present in structural element (B), which are completely or partially covalently or non-covalently linked to aliphatic fatty acids and / or bioactive substances (structural element (C)).
[0014] Secondly, it was also found that modified poly(dicarboxylic acid multiol esters) can be mixed with suitable biocompatible organic solvents and injected. Examples of implementation: Example 1:
[0015] Fatty acid-modified poly(glycerol adipates) can be synthesized by the following or similar methods / 10-16 / .
[0016] Adipic acid is used as structural element (A) (dicarboxylic acid), while glycerol, which has three hydroxyl groups, serves as the polyol (structural element (B)). Figure 1The polymer backbone polyglycerol adipate is produced, for example, by an enzymatic reaction of divinyl adipate or
[0017] Dimethyl adipate with glycerol in tetrahydrofuran or another suitable solvent is carried out / 10 / . Examples of fatty acids used are lauric, stearic, behenic, or oleic acid. The degree of substitution of the fatty acids is between 1% and 100% (based on the hydroxyl groups of the poly(glycerol adipate) ( Figure 2 ).
[0018] The oleic and lauric acid-modified polymers have a liquid consistency at a temperature of 20°C (room temperature). Furthermore, the following are disclosed outside the scope of the invention: stearic and behenic acid-modified polymers have a solid consistency at 20°C. They melt in the range of 30-45°C (stearyl-modified poly(glycerol dipate)) and between 50°C and 65°C (behenyl-modified poly(glycerol dipate)), respectively.
[0019] With behenyl- and stearyl-moldiified polymers, an implantable mold can be obtained very easily by melting or extrusion processes. Example 2:
[0020] Lauric acid-modified poly(glycerol dipate) (degree of esterification 25% based on free hydroxyl groups of the polyglycerol dipate) is injected through a 25-gauge needle in phosphate-buffered saline (PBS, diluted 1:10). A spherical depot forms ( Figure 3 ). Example 3:
[0021] Lauric acid-modified poly(glycerol dipate) (95% esterification based on free hydroxyl groups of the polyglycerol dipate) is injected through a 25-gauge needle in phosphate-buffered saline (PBS, diluted 1:10). A spherical deposit forms. Example 4:
[0022] Oleic acid-modified poly(glycerol dipate) (degree of esterification 15% based on free hydroxyl groups of the polyglycerol dipate) is injected through a 25-gauge needle in phosphate-buffered saline (PBS, diluted 1:10). A spherical deposit forms. Example 5:
[0023] Oleic acid-modified poly(glycerol dipate) (92% esterification based on free hydroxyl groups of poly(glycerol dipate)) is injected through a 25-gauge needle in phosphate-buffered saline (PBS, diluted 1:10). A spherical deposit forms. Example 6:
[0024] Fatty acid-modified poly(glycerol sebacate) polymers are prepared analogously to the synthesis routes published in / 10 / . Sebabic acid is used as structural element (A) (dicarboxylic acid), and glycerol, which possesses three hydroxyl groups, serves as the polyol (structural element (B)). Figure 1The polymer backbone poly(glycerol sebacate) is produced, for example, by an enzymatic reaction of divinyl sebacate with glycerol in tetrahydrofuran or another suitable solvent / 10 / . Examples of fatty acids used include lauric, stearic, behenic, or oleic acid. The degree of fatty acid substitution ranges from 1% to 100% (based on the hydroxyl groups of the poly(glycerol sebacate)). Example 7 Stearyl-modified poly(sorbitol adipate)
[0025] The polymer backbone is prepared from the polyol sorbitol and the dicarboxylic acid adipic acid analogously to the procedures published for poly(glycerol adipate) and modified with stearic acid. At a degree of esterification of 30% (30% esterification based on the free hydroxyl groups of the poly(sorbitol adipate)), a polymer is formed that is solid at room temperature and melts at 43°C.
[0026] An implantable mold can be obtained very easily through melting or extrusion processes. Example 8:
[0027] In vitro release of the fluorescent dye 1,1'-Dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DII): Lauryl-substituted poly(glycerol adipate) polymers were loaded with the fluorescent dye DII (1% w / w) and incubated in vitro in PBS at 37°C in 60 microliters.
[0028] The following curves in Figure 4 The results show a controlled release of the model substance in vitro. The number following the L symbolizes the degree of substitution of lauric acid relative to free hydroxyl groups of the poly(glycerol adipate). Example 9: In vivo release of the fluorescent dye DII from lauryl-substituted poly(glycerol adipate)
[0029] The polymers were loaded with the fluorescent dye 1,1'-Dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DII) (0.5-1 % w / w) and 50 microliters were injected subcutaneously into SKH1 mice.
[0030] In vivo fluorescence images of the DII-loaded lauryl-modified poly(glycerol adipate) polymers after subcutaneous injection (50 microliters) into SKH1 nude mice confirmed in vivo release by visible signals. The degree of lauric acid substitution was 95% and 25%, respectively.
[0031] The results show a controlled in vivo release over several weeks to months. Surprisingly, it was found that the more lipophilic implant (95% substitution based on free hydroxyl groups) released more rapidly than the less substituted implant (25% based on free hydroxyl groups). These results demonstrate that the release of substances in vivo can be controlled by the degree of substitution with the fatty acid. Example 10:
[0032] Production of liquid dexamethasone-containing implants. Dexamethasone is incorporated into fatty acid-modified poly(glycerol adipate) at a concentration of 10% w / w. Incorporation of the liquid polymers (lauryl- and oleyl-modified poly(glycerol adipate)) can be carried out at room temperature. Due to their liquid consistency, the dexamethasone-loaded (lauryl- and oleyl-modified poly(glycerol adipate)) polymers can be injected. Reference example
[0033] Production of solid dexamethasone-containing implants. Dexamethasone is incorporated into fatty acid-modified poly(glycerol adipate) at a concentration of 20% w / w. The polymers, which are solid at room temperature (e.g., stearyl-modified and behenyl-modified poly(glycerol adipate)), are melted, and the active ingredient is homogeneously incorporated. By melting and solidifying, compression, or extrusion, a suitable mold (e.g., discs or rods) can be obtained from the solid polymers, which can then be implanted. Reference example 12:
[0034] Nifidipin is incorporated into stearyl-modified poly(sorbitol adipate) at a concentration of 10% w / w. For this purpose, the polymer is melted at 50 °C and the active ingredient is homogeneously dispersed under light protection. The molten, drug-containing polymer is then solidified in a suitable mold to achieve the desired size and shape. Reference example 13:
[0035] Drug-containing in situ implant. Stearyl-modified poly(glycerol adipate) is combined with N-Methylpyrrollidone (NMP) is mixed in a 1:1 w / w ratio. Leuprolin acetate is homogeneously incorporated at a concentration of 5% w / w. The preparation can be administered through a 25-gauge cannula and forms an implant in situ upon contact with water or within the body. Reference example 14:
[0036] Implant with covalently bound betulinic acid. The polymer backbone of poly(glycerol adipate) is synthesized according to the procedures described in the literature / 10 / . Instead of the fatty acids described in the literature / 10 / , the bioactive substance betulinic acid is covalently linked to the polymer backbone in an analogous reaction. The resulting betulinic acid poly(glycerol adipate) can either be melted into a desired implant shape or applied as an in situ implant using a biocompatible organic solvent (e.g., NMP). Bibliography
[0037] / 1 / Mäder et al., Biomaterials, 17(4), 457-461 (1996) / 2 / K Mäder, G Bacic, A Domb, O Elmalak, R Langer and HM Swartz. J Pharm Sci 86: 126, (1997). / 3 / Liu and Schwendeman, Molecular Pharmaceutics, 9(5), 1342-1350 (2012) / 4 / A Lucke, J Kiermaier and A Göpferich. Pharm Res 19: 175, (2002). / 5 / A Lucke and A Göpferich. Eur J Pharm Biopharm 55: 27, (2003). / 6 / Beck-Broichsitter et al., Parenteral depot dosage forms-microparticles, in: Innovative dosage forms, edited by Mäder and Weidenauer, Wissenschaftliche Verlagsgesellschaft Stuttgart, pp. 235-262, (2010) / 7 / S Kempe and K Mäder. J Control Release 161: 668, (2012) / 8 / BJ Kline, EJ Beckman, AJ Russell. J Am Chem Soc 120: 9475 (1998) / 9 / Shafioul, Azam Sharif Mohammed; Pyo, Jung In; Kim, Kwan Soo; Cheong, Chan Seong: Synthesis of poly (glycerol-co-dioate-co-butanedioate-co-xanthorrhizol) ester and a study of chain length effect on pendant group loading. Journal of Molecular Catalysis B: Enzymatic (2012), 84, 198-204., DOI:10.1016 / j.molcatb.2012.05.022 / 10 / Naolou, T.; Weiss, V. M.; Conrad, D.; Busse, K.; Maeder, K.; Kressler, J.: Fatty acid modified poly(glycerol adipate) - polymeric analogues of glycerides. ACS Symposium Series(2013), 1135 (Tailored Polymer Architectures for Pharmaceutical and Biomedical Applications), 39-52, 14 pp., DOI:10.1021 / bk-2013-1135.ch004 / 11 / Kressler, Joerg; Naolou, Toufik; Conrad, Delf; Busse, Karsten; Amado, Elkin; Weiss, Verena; Maeder, Karsten: Fatty acid modified poly(glycerol adipate)-polymeric analogues of glycerides. Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (2012), 53(1), 567-568. / 12 / Weiss, Verena M.; Naolou, Toufik; Amado, Elkin; Busse, Karsten; Maeder, Karsten; Kressler, Joerg Formation of Structured Polygonal Nanoparticles by Phase-Separated Comb-Like Polymers. Macromolecular Rapid Communications(2012), 33(1), 35-40., DOI:10.1002 / marc.201100565 / 13 / Orafai, Hossein; Kallinteri, Paraskevi; Garnett, Martin; Huggins, Sean; Hutcheon, Gillian; Pourcain, Cristopher Novel poly(glycerol-adipate) polymers used for nanoparticle making: a study of surface free energy. Iranian Journal of Pharmaceutical Research (2008), 7(1), 11-19 / 14 / Puri, Sanyogita; Kallinteri, Paraskevi; Higgins, Sean; Hutcheon, Gillian A.; Garnett, Martin C.: Drug incorporation and release of water soluble drugs from novel functionalized poly(glycerol adipate) nanoparticles. Journal of Controlled Release (2008), 125(1), 59-67 / 15 / Kallinteri, Paraskevi; Higgins, Sean; Hutcheon, Gillian A.; St. Pourcain, Christopher B.; Garnett, Martin C.: Novel Functionalized Biodegradable Polymers for Nanoparticle Drug Delivery Systems. Biomacromolecules (2005), 6(4), 1885-1894 / 16 / WO 2004096178 A1 20041111 - Garnett, Martin Charles; Hutcheon, Gillian; Higgins, Sean; Kallinteri, Paraskevi; St.Pourcain, Chris: Nano and microparticle drug delivery systems comprising polyesters containing aliphatic dicarboxylate residues and residues of aliphatic polyols . Explanations of the characters
[0038] Figure 1 :Simplified (left) and more detailed (right) basic structure of modified poly(dicarboxylic acid multiol) esters. Structural element (A): Dicarboxylic acid. Structural element (B): Polyol (diol, triol, or higher-grade polyol). Structural element C: Covalently bound active ingredient or excipient. The biodegradable polymer backbone is formed from the esterification of dicarboxylic acids (structural element (A)) and polyols (structural element (B)). In this process, two hydroxyl groups of the polyol are esterified. In higher-grade polyols (number of hydroxyl groups greater than or equal to three), the hydroxyl groups remaining free after formation of the polymer backbone can be partially or fully covalently linked to bioactive substances or excipients (e.g., fatty acids) (structural element (C)). Figure 2 :Structural examples of fatty acid-modified poly(glycerol adipate). The polymer backbone is composed of poly(glycerol adipate). Some of the hydroxyl groups remaining free after the formation of the polymer backbone are esterified with fatty acids (lauric acid, stearic acid, behenic acid, oleic acid). Figure 3 : Schematic representation of the behavior of lauryl-substituted poly(glycerola dipate) polymers after in vitro injection with a 25-gauge needle into phosphate-buffered saline (PBS buffer, pH 7.4, diluted 1:10 with double-distilled water) (a); after one minute (b) and 6 hours (c) post-injection. The implant sinks to the bottom after injection and forms a sphere-like shape. Figure 4 :In vitro time dependence of the fluorescence intensity of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DII)-loaded lauryl-substituted poly(glyceroladipic acid) polymers. The model compound is released in vitro in a controlled manner over several weeks.
Claims
1. Injectable carrier systems based on modified aliphatic polyesters for use in humans or animals targeting the controlled release of a bioactive substance for therapeutic and / or diagnostic purposes consisting of polymers, the basic structure of which is characterized in a comb-like structure consisting of structural elements (A), (B) and (C); where the polymer backbone is formed by the structural elements (A) and (B) consisting of aliphatic dicarboxylic acids (A) and polyols (B) containing three or more OH groups, wherein: two hydroxyl groups of the polyol (B) with the dicarboxylic acids of the structural element (A) are esterified to form a linear polymer backbone, after formation of the polymer backbone consisting of the structural elements (A) and (B) and linked by ester bonds, one (for triols) or several (number of hydroxyl groups in the Polyol > 3) free hydroxyl groups are present that are fully or partially related to aliphatic fatty acids and / or bioactive substances covalent or non-covalent (structural element (C)).
2. The carrier systems according to claim 1, characterized in that the aliphatic dicarboxylic acids of the structural element (A) of the following general structure have a molecular moiety R1 between the two carboxy groups, which has an alkyl structure and is saturated or unsaturated, branched or unbranched with R1 = 0 (zero) and ≤ 40 (forty) carbon atoms, preferably 1 (one) to 14 (fourteen) carbon atoms, particularly preferably 4 (four) to 10 (ten) carbon atoms.
3. The carrier systems according to claim 1, characterized in that the polyol structural element (B) may consist of a mixture of triols and higher valent polyols or mixtures of the same.
4. The carrier systems according to claims 1 and 3, characterized in that glycerol, erythritol, xylitol, mannitol, sorbitol, lactose, sucrose, trehalose, glucose, maltose, isomalt and / or maltitol are used as the polyol.
5. The carrier systems according to claims 1, 3 and 4, characterized in that the polyol (B) is covalently linked to other substances by means of the structural element (C), so that a comb-like polymer structure is created, wherein the degree of linkage is between 0,1 and 100% of the free hydroxyl groups still present after the formation of the polymer backbone.
6. The carrier systems according to claims 1 to 5, characterized in that the structural element (C) is a carboxylic acid or one or more bioactive substance(s), which is (are) linked to the polyol structure (B) by an ester bond, the fatty acid being saturated or unsaturated and the degree of esterification being between 0 (zero) and 99.9% of the free hydroxyl groups.
7. The carrier systems according to claims 1 to 6, characterized in that the number of carbons of the carboxylic acid is between 2 (two) and 22 (twenty-two), in particular between 8 (eight) and 22 (twenty-two) carbon atoms, such as caprylic acid (octanoic acid), capric acid (decanoic acid), lauric acid (dodecanoic acid), myristic acid (tetradecanoic acid), Palmitic acid (hexadecanoic acid), stearic acid (octadecanoic acid), oleic acid ((9Z)-octadeca-9-enoic acid), linoleic acid ((9Z,12Z)-octadeca-9,12-dienoic acid), linolenic acid ((9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid).
8. The carrier systems according to claims 1 to 7, in which the bioactive substance(s) is (are) incorporated (not covalently bound) or covalently bound, wherein, in case of incorporation (non-covalent binding), the bioactive substance(s) are present in dissolved, emulsified or suspended form, and in case of covalent binding, the bioactive substance(s) is (are) covalently bound to the polymer carrier material by a chemical reaction of one of the functional groups present in suitable functional groups of the bioactive substance(s), e.g., an acid group, with the free hydroxyl groups present in the structural element (B) is covalently bound to the polymeric carrier material by an ester bond.
9. The carrier systems according to claim 8, characterized in that the bioactive substances contained are hydrophilic, amphiphilic or hydrophobic in nature when having a low, medium or high molecular weight and are present in dissolved, emulsified or suspended form.
10. The carrier systems according to claims 8 and 9 characterized in that substances belonging to the class of antibiotics, antiinfectives, cytostatics or other antineoplastic agents and protectives, local anesthetics, analgesics, neuropharmaceuticals, hormones, immunomodulators, immunosuppressants, antifungals, anti-inflammatory agents, analgesics, anti-hemorrhagics, anti-fibrinolytics, vitamins, hemostatics, anti-inflammatory drugs, beta-receptor and calcium channel blockers, corticoids, withdrawal agents / agents for the treatment of addiction, fibrinolytics, anti-hypoxics, cardiovascular agents, anticoagulants, antiparasitic agents, anti-caries agents, antiperiodontics, ophthalmics, otologics, sex hormones and their inhibitors, antiparkinsonian agents and other agents for extrapyramidal disorders, psychopharmaceuticals, sera, immunoglobulins, vaccines, minerals, platelet aggregation inhibitors, tuberculosis agents, diuretics, gastrointestinal agents, anti-obesity agents, analeptics, antirheumatics, anti-allergics, anti-anemics, anti-arrhythmics, anti-dementia agents, antidiabetics, antidotes, antiemetics, antivertigo agents, antiepileptics, antihypertensives, anti-hypoglycemics, anti-hypotensive agents, antitussives, expectorants, anti-arteriosclerosis agents, inhibitors of the renin-angiotensin-aldosterone system, broncholytics, antiasthmatics and other respiratory tract agents, cholinergics, antiseptics, diagnostics and diagnostic preparation agents, diuretics, enzyme inhibitors, enzyme deficiency preparations and transport proteins, geriatrics, anti-gout agents, gynecologics, hepatics, hypnotics, sedatives, pituitary hormones, hypothalamic hormones, regulatory peptides and analogs and their inhibitors, immunomodulators, cardioactive agents, coronary agents, lipid lowering agents, local anesthetics, gastrointestinal agents, migraine agents, muscle relaxants and their reversors, anesthetics, neuropathic preparations and other neurotropic agents, osteoporosis agents / calcium / bone metabolic regulators, thyroid therapeutics, spasmolytics and anticholinergic agents, mood remedies, urologies and agents for the treatment of hyperkalemia and hyperphosphatemia, venous therapeutics, wound and scar treatments are used as bioactive substances.
11. The carrier systems according to claims 1 to 10 characterized in that the concentration of modified poly(dicarboxylic acid-multiol esters) is 0.1% to 99.9999% (m / m).
